Palbociclib

Common card · No. 484628

Palbociclib, sold under the brand name Ibrance among others, is an anti-cancer medication used for the treatment of HR-positive and HER2-negative breast cancer. It was developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy. The most common side effects include neutropenia (low blood levels of neutrophils, a type of white blood cell that fights infection), infections, leucopenia (low white blood cell counts), tiredness, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), anemia (low red blood cell counts), diarrhea, alopecia (hair loss), and thrombocytopenia (low blood platelet counts). The most common severe side effects include neutropenia, leucopenia, infections, anemia, tiredness, and increased blood levels of liver enzymes (aspartate and alanine transaminases).

Read on Wikipedia · Image Fuse809 (talk), CC BY-SA 4.0